In previous studies, by using protein misfolding cyclic amplification technology, researchers were able to differentiate AβO levels by catalyzing the misfolding and amplification of Aβ aggregates by spiking Aβ42 into the CSF of patients with AD and control individuals [44]. Here, ABO is linked to Alzheimer disease.